



IBA RadioPharma Solutions Users Meeting: Joining Forces to Improve the Quality of Cancer Diagnosis

Bern, Switzerland, September 22, 2015 – From September 20th to 25th, IBA (Ion Beam Applications S.A.) is bringing together more than 130 users of its RadioPharma solutions at the Cyclone and Synthera Users meeting. This meeting is hosted by SWAN Isotopen AG, a commercial radioisotope production facility on the campus of the University Hospital of Bern. The meeting includes five days of in-depth discussions, technical insights and ideas on how PET production facilities can further advance towards its ultimate goal: to improve the quality of cancer diagnosis. Over 130 attendees from radiopharmaceuticals centers all over the world take advantage of this unique opportunity to interact with their peers.

Highlighting the achievements of IBA is not the sole purpose of such a user meeting: it also provides an opportunity to express concerns, offer suggestions for improvement, share experiences and collaboratively seek solutions. IBA believes this to be the best way to maintain its lead in radiopharmaceuticals production equipment advancement. The users appreciate the opportunity to discuss solutions in an open and supportive atmosphere.

A visit to the state-of-the-art radiopharmacy SWAN Isotopen AG in small groups updates the audience on advanced equipment and proven methods of radiopharmaceuticals production. The facility is one of the most modern radiopharmaceutical production sites in Europe situated in the heart of a renowned university hospital.

A combination of presentations and workshops ensures a good balance between the technical aspects and the best practices of radiopharmaceuticals production, with the parallel workshop sessions offering every attendee the chance to pick their personal favorites. The first three days focuses on the current use of and new approaches for cyclotrons and targetry systems. Days 4 and 5 will focus on the future potential developments of the chemistry systems. A high level of interaction between presenters and attendees is encouraged throughout the meeting.

Bruno Scutnaire, Vice President RadioPharmacy Solutions at IBA, said: "For IBA, our customers' feedback is incredibly valuable. The users meeting offers the ultimate opportunity to set different point of view, confront and align the practical knowledge of us as manufacturers and as users. We have realized how, year by year, spirits rise as the community is growing, and we hope to gather input to further enhance our solutions and improve the user experience for IBA customers."

Konrade von Bremen, Director at SWAN Isotopen AG, said "Our close collaboration with IBA is of vital importance to assure the daily reliable production with the highly complex equipment. It is a great pleasure for SWAN Isotopen AG to host this prestigious meeting and to share our experience with the other users from all over the world."

- END -



Notes to Editors

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1,100 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

About IBA RadioPharma Solutions

Based on longstanding expertise, IBA RadioPharma Solutions supports hospitals and radiopharmaceutical distribution centers with their in-house radioisotopes production by providing them with global solutions, from project design to the operation of their facility. In addition to high-quality production equipment, IBA has developed in-depth experience in setting up GMP-compliant radiopharmaceuticals production centers.

About SWAN Isotopen AG

SWAN-Isotopen AG is a spin-of company of the University Hospital of Bern, Inselspital, producing full GMP radiopharmaceuticals. The SWAN production site hosts a multidisciplinary research team of high energy physicists and radiochemist of the University of Bern.

For more information please contact

IBA

Thomas Ralet

Vice-President Corporate Communication

+32 10 47 58 90

communication@iba-group.com

SWAN Isotopen AG

Dr. med. Konrade von Bremen

CEO

+41 31 384 00 50